Data collection:
The demographic information, including age, gender and smoking, and full
medical history, were entered into the study checklist.
The patients’ examinations in the period of hospitalization were
recorded, as well. The assessments included the admission levels of
hemodynamic parameters (oxygen saturation (O2 sat), pulse rate (PR),
systolic (SBP) and diastolic blood pressure (DBP)) and the on admission
laboratory assessments (polymorphonuclear cells absolute count (PMN),
absolute lymphocyte count (lymph count), hemoglobin (Hb), platelet count
(PLT), troponin level, fibrin degradation product (FDP), fibrinogen,
d-dimer, ferritin, C-reactive protein (CRP), prothrombin time (PT),
partial thromboplastin time (PTT), international normalized ratio (INR),
albumin (Alb) and lactate dehydrogenase (LDH)).
Anticoagulation in the studied group was classified as no
anticoagulation, prophylactic, intermediate and therapeutic dose. Type
of anticoagulation prior to thrombotic event was studied in the case
group. Prophylactic doses were 5000 IU of subcutaneous unfractionated
heparin (UFH) (twice daily), or 40 mg of subcutaneous low molecular
weight heparin (LMWH) (once daily) or 10 mg of oral rivaroxaban (daily).
Intermediate doses included 7500 IU of subcutaneous UFH (twice daily),
or 60 mg of subcutaneous LMWH (daily), or 40 mg of subcutaneous LMWH
(twice daily). The therapeutic doses were determined as 80 IU/kg of IV
UFH followed by infusion of 18 IU/kg/h or 1 mg/kg of subcutaneous LMWH
(twice daily) or 15 mg of oral rivaroxaban (twice daily).
The hospitalization-related characteristics were gathered as well. These
data were mobility during the hospitalization (complete bed rest (CBR)
or relative bed rest (RBR)), type of ventilation (non-invasive
ventilation/ intubation), ICU admission requirement, length of
hospitalization, the time between hospitalization to ICU admission, and
death incidence.